Midiana (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Midiana, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy by suppressing ovulation, thickening cervical mucus, and altering the endometrium in women of reproductive age, and is formulated for once‑daily administration as a reliable method of contraception.

GNH USA supplies Midiana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing quality‑assured products that meet European Union regulatory standards, and supports timely delivery to global markets.

Midiana, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy.

Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. Regulation of menstrual cycle: helps achieve more predictable bleeding patterns and reduces cycle irregularities. Management of dysmenorrhea: may lessen menstrual pain associated with ovulatory cycles.

Midiana may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain - Breakthrough bleeding

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Severe hypertension - Hepatocellular adenoma (liver tumor) - Allergic reactions (rash, angioedema)

Before prescribing Midiana, clinicians should consider several safety factors.

Pregnancy contraindication: do not use during pregnancy; discontinue immediately if pregnancy occurs. Smoking restriction: avoid use in women over 35 who smoke due to increased cardiovascular risk. Cardiovascular assessment: evaluate history of thromboembolic disorders before initiating therapy. Liver disease: use with caution in patients with active liver disease or hepatic dysfunction. Blood pressure monitoring: check blood pressure regularly during treatment. Store at room temperature: keep below 25°C in the original packaging, protect from moisture.

Midiana can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): reduce contraceptive efficacy. - Certain antiretrovirals (e.g., protease inhibitors boosted with ritonavir): may lower hormone levels. - St. John’s wort: may markedly decrease plasma concentrations of the hormones.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone exposure. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): can elevate plasma levels. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): may modestly affect hormone metabolism.